Smith & Nephew SNATS

Smith & Nephew SNATS Net Margin

The Net Profit Margin of Smith & Nephew SNATS (SNN) as of Nov 3, 2026 is 10.14 %. In the previous year, Net Profit Margin was 7.09 % — a change of 42.99% (higher).

Net Margin

10.14 %

YoY

42.99%

Last updated:

Net Profit Margin of Smith & Nephew SNATS is 2025 10.14 % . Net Profit Margin of Smith & Nephew SNATS was 2024 7.09 % . It decreases by 42.99% higher compared to the previous year.

Smith & Nephew SNATS's net margin stands at 10.1%, broadly stable from 10.1% several years earlier.

The Smith & Nephew SNATS Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
13.52 USD
Jan 1, 2019
11.68 USD
Jan 1, 2020
9.82 USD
Jan 1, 2021
10.05 USD
Jan 1, 2022
4.28 USD
Jan 1, 2023
4.74 USD
Jan 1, 2024
7.09 USD
Jan 1, 2025
10.14 USD
The Smith & Nephew SNATS Net Margin history
YEARNet MarginYoY
10.14 %+42.99%
7.09 %+49.62%
4.74 %+10.84%
4.28 %-57.47%
10.05 %+2.33%
9.82 %-15.87%
11.68 %-13.62%
13.52 %-16.01%
16.10 %-4.14%
16.79 %+89.79%
8.85 %-18.46%
10.85 %+8,391.65%
0.13 %-27.48%
0.18 %+29.28%
0.14 %-12.19%
0.16 %+24.05%
0.13 %+26.16%
0.10 %+5.74%
0.09 %-65.01%
0.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS Stock analysis

What does Smith & Nephew SNATS do? Smith & Nephew SNATS Inc operates in the medical device sector, focusing on orthopaedic implants and surgical solutions. The company generates revenue through knee and hip implant products used in joint replacement procedures, including revision surgeries. Its trauma and extremities segment offers internal and external devices for fracture stabilization and deformity correction. Sports Medicine & ENT segment sells joint repair products, arthroscopic equipment, and tissue resection devices for minimally invasive surgeries. Advanced Wound Management provides specialized wound care solutions, though specific products are not detailed in the description. The primary buyers are healthcare providers and hospitals globally, particularly in the United Kingdom, United States, and international markets. Orthopaedics and Sports Medicine & ENT segments target surgeons and orthopaedic specialists, while Advanced Wound Management serves wound care professionals. The company’s products are sold under its own brand, with no external brand names mentioned in the description. Revenue streams include direct sales of medical devices to hospitals and clinics, with no mention of subscription models or service-based fees. The company’s focus on surgical solutions and implants drives its market position, with key segments defined by product categories rather than geographic regions. No additional revenue streams like data services or digital platforms are referenced in the business description. Smith & Nephew SNATS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Smith & Nephew SNATS stock

Net Profit Margin of Smith & Nephew SNATS is 10.14 % in 2025.

Net Profit Margin of Smith & Nephew SNATS changed from 7.09 % to 10.14 %, representing a 42.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Smith & Nephew SNATS since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Smith & Nephew SNATS with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Smith & Nephew SNATS

All Key Metrics — Smith & Nephew SNATS